Imaging findings in children with proliferative disorders following multivisceral transplantation

Hryhorczuk, Anastasia L.; Kim, Heung Bae; Harris, Marian H.; Vargas, Sara O.; Zurakowski, David; Lee, Edward Y.

doi:10.1007/s00247-015-3303-2

Cited by 7 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on single-center experiences, the overall incidence of PTLD following ITx ranges from 11-21%, [2][3][4][5][6][7] with pediatric ITx recipients at greatest risk, 8 likely because they are more often EBV-naïve at the time of transplant. In addition to age and EBV status, other risk factors for PTLD include immunosuppression exposure, past history of rejection, splenectomy, and/or receipt of donor spleen.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical characteristics and outcomes of PTLD following intestinal transplantation

Wozniak

Mauer

Venick

et al. 2018

Clinical Transplantation

View full text Add to dashboard Cite

Post-transplant lymphoproliferative disease (PTLD) has the highest incidence following intestinal transplantation (ITx). Our center has seen a recent increase in PTLD. Our aim was to review a single-center PTLD experience with a focus on clinical characteristics and outcomes. We completed a retrospective review of biopsy-proven PTLD cases using a prospectively maintained database of 115 ITx recipients transplanted between 1991 and 2014. Nineteen (17%) ITx recipients developed 25 PTLD cases during a median follow-up time of 6.4 (1.6-14.6) years. The incidence of early PTLD was 6% (n = 7). There was a trend toward increased risk of PTLD in children compared with adults (P = .11) and a significantly increased risk of PTLD in re-ITx compared with primary ITx recipients (P = .03). Most PTLD cases were diagnosed between 2010 and 2014 (n = 14). All early PTLD cases were EBV+ on in situ hybridization. Overall graft and patient survival are 68% and 74%, respectively. Second episodes of PTLD were diagnosed in 43% of surviving pediatric patients. Our program has a low incidence of early PTLD with overall excellent graft and patient survival following diagnosis. However, we have also seen a rising incidence of late PTLD. The cause of the increase is unknown as no major changes in immunosuppression protocols have occurred since 1999.

show abstract

Section: Introductionmentioning

confidence: 99%

“…For these 14 patients, the median number of EBV viremia episodes was 3(1)(2)(3)(4)(5)(6)(7)(8) and the median duration of EBV viremia was 621 (7-3156) days. As noted inTable 4, 2 patients (patient 16 and 18) had received past treatment with rituximab for persistent moderate to high EBV viremia 2.1 and 4.8 years prior to PTLD diagnosis, respectively.…”

mentioning

confidence: 99%